3DHISTECH and Epredia open pathology innovation incubator to accelerate advancements in cancer diagnostics

Two leading pathology and diagnostics companies, 3DHISTECH of Hungary and Epredia, a member of PHC Group (headquartered in Japan), announce the opening of the Pathology Innovation Incubator in Budapest to develop methods and equipment for faster and more precise diagnosis of cancer and tumor lesions. The opening was announced today at an event with the Hungarian Ministry of Foreign Affairs and Trade.

3DHISTECH and Epredia open pathology innovation incubator to accelerate advancements in cancer diagnostics

Image Credit: 3DHISTECH

The aim of the Pathology Innovation Incubator, founded by Epredia and 3DHISTECH, is to develop and improve solutions that revolutionize tumor diagnostics and enable more effective treatment of cancer. The collaboration between the two companies, who are commercial partners in digital slide scanning technology for pathology laboratories, is designed to enable the practical implementation of scientific and theoretical ideas. Both Epredia and 3DHISTECH will support the Pathology Innovation Incubator financially and through knowledge transfer and technology sharing. The development of the Pathology Innovation Incubator was completed in just one year.

The opening ceremony today also marks the start of the first dedicated project for the Pathology Innovation Incubator, with a budget of 1.5 billion HUF (approximately 4 million USD). The aim of that project is to develop a highly complex combined medical technology solution for immunohistochemical (IHC) tests, which are the basis of cancer diagnostics, to improve the effectiveness of personalized diagnostics and support treatment decisions for patients.

Steven Lynum, President of Epredia, said that as the number of cancer patients worldwide continues to increase year after year and cancer diagnostics becomes increasingly complex, advancing innovative diagnostics solutions can make a direct impact on families and society as a whole.

“At Epredia, every second of the day 44 of our products are employed in the fight against cancer. We believe we can to make this fight even more effective through improved cancer screening and early diagnosis. We want to develop effective and reliable diagnostic solutions to the current challenges in patient care, thereby increasing the range of options currently available. This is the purpose of our new investment, the Pathology Innovation Incubator, which we have launched together with 3DHISTECH. The collaboration between our companies and our joint success in digital pathology goes back several years. Joint development now offers a forward-looking solution in the field of immunohistochemistry. We are excited to leverage the extensive knowledge base, deep expertise and labor market opportunities available here in Hungary. Our goal is for the Pathology Innovation Incubator to become a global scientific development center that will translate today’s scientific knowledge into clinical applications that contribute to the early and rapid diagnosis of cancer,” said Steven Lynum.

At the opening ceremony in Budapest today, Dr. Béla Molnár, founding CEO of 3DHISTECH, added:

“3DHISTECH has had a highly successful presence in the U.S. for 10 years, and a partnership with Epredia’s Anatomical Pathology Division for several years. Together we have tripled the number of pathology digitalization projects under this outstanding partnership. This has proven the value of deepening our collaboration, and we are using this excellent opportunity to create and launch the Pathology Innovation Incubator together. This is not only a financial investment on our part, but also a sharing of know-how from a research perspective, combining our professional knowledge and experience, as well as our industry knowledge and network of contacts, with Epredia’s resources to create a unique and world-class innovation center. From an investor perspective, this enables an increase in the market potential of 3DHISTECH and Epredia. In addition to our IHC project, we are already seeing a number of R&D innovations in the incubator center that are bringing together cutting-edge Japanese, American and Hungarian technologies, as well as medical, biological and engineering solutions.”

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    3DHISTECH Ltd.. (2023, September 25). 3DHISTECH and Epredia open pathology innovation incubator to accelerate advancements in cancer diagnostics. News-Medical. Retrieved on July 20, 2024 from https://www.news-medical.net/news/20230925/3DHISTECH-and-Epredia-open-pathology-innovation-incubator-to-accelerate-advancements-in-cancer-diagnostics.aspx.

  • MLA

    3DHISTECH Ltd.. "3DHISTECH and Epredia open pathology innovation incubator to accelerate advancements in cancer diagnostics". News-Medical. 20 July 2024. <https://www.news-medical.net/news/20230925/3DHISTECH-and-Epredia-open-pathology-innovation-incubator-to-accelerate-advancements-in-cancer-diagnostics.aspx>.

  • Chicago

    3DHISTECH Ltd.. "3DHISTECH and Epredia open pathology innovation incubator to accelerate advancements in cancer diagnostics". News-Medical. https://www.news-medical.net/news/20230925/3DHISTECH-and-Epredia-open-pathology-innovation-incubator-to-accelerate-advancements-in-cancer-diagnostics.aspx. (accessed July 20, 2024).

  • Harvard

    3DHISTECH Ltd.. 2023. 3DHISTECH and Epredia open pathology innovation incubator to accelerate advancements in cancer diagnostics. News-Medical, viewed 20 July 2024, https://www.news-medical.net/news/20230925/3DHISTECH-and-Epredia-open-pathology-innovation-incubator-to-accelerate-advancements-in-cancer-diagnostics.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.